PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm.

Whooley, J; Alazzawi, M; Donlon, N E; Bolger, J C; Robb, W B

Whooley, J; Alazzawi, M; Donlon, N E; Bolger, J C; Robb, W B.

Afiliación

Whooley J; National University of Ireland, Galway (NUIG), Ireland.
Alazzawi M; Department of Upper Gastrointestinal Surgery, Beaumont Hospital, Dublin 9 Co Dublin, Ireland.
Donlon NE; Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.
Bolger JC; Department of Upper Gastrointestinal Surgery, Beaumont Hospital, Dublin 9 Co Dublin, Ireland.
Robb WB; Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.

Dis Esophagus ; 35(5)2022 May 10.

Article en En | MEDLINE | ID: mdl-34553222

Asunto(s)

Neoplasias Esofágicas; Neoplasias Gástricas; Antígeno B7-H1/metabolismo; Neoplasias Esofágicas/tratamiento farmacológico; Neoplasias Esofágicas/patología; Unión Esofagogástrica/patología; Humanos; Inhibidores de Puntos de Control Inmunológico; Receptor de Muerte Celular Programada 1/uso terapéutico; Neoplasias Gástricas/patología

Palabras clave

PD-1 inhibitors; PD-L1; esophageal cancer; immune checkpoint inhibitors; immunotherapy; nivolumab; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Dis Esophagus Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irlanda

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google